Archive · 29 Jan 2026
Gland Pharma Q3 Profit, Revenue Beat Estimates
Gland Pharma, a pharmaceutical company, recently announced its results for the last three months of 2023.
They made more money than expected, with their profit increasing by 27.5% compared to the same time last year.
Their total sales also went up by 22.5%.
The company did well because they launched new products and did better in important markets like the US and Europe.
They also spent more on research and development to create new, complex medicines.
Overall, it was a good quarter for Gland Pharma.
Gland Pharma's Q3 net profit rose 27.5% YoY to ₹261.4 crore, beating estimates.
Revenue grew 22.5% YoY to ₹1,695 crore, with strong US and Europe traction.
EBITDA increased 20.8% YoY to ₹434.9 crore, with a stable margin of 25.6%.
The company launched nine new molecules in the US and filed nine ANDAs.
R&D spending increased to ₹65 crore, focusing on complex product development.
- Who
- Gland Pharma
- What
- Reported Q3 results with profit and revenue beating estimates
- When
- December quarter (Q3)
- Where
- Global markets, with strong traction in the US and Europe
- Why
- Strong execution, new product launches, and improving contribution from base and CDMO businesses
- Net Profit
- ₹261.4 crore (up 27.5% YoY)
- Revenue
- ₹1,695 crore (up 22.5% YoY)
- EBITDA
- ₹434.9 crore (up 20.8% YoY)
- EBITDA Margin
- 25.6% (stable YoY)
- R&D Spending
- ₹65 crore (5.4% of revenue)
- US Filings
- 384 cumulative ANDAs
- New Launches
- 9 molecules in the US
- New Filings
- 9 ANDAs in Q3